

Toshifumi Hibi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5389816/publications.pdf>

Version: 2024-02-01

204
papers

8,871
citations

61984

43
h-index

49909

87
g-index

215
all docs

215
docs citations

215
times ranked

6914
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. <i>Intestinal Research</i> , 2023, 21, 110-125.	2.6	9
2	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 105-115.e14.	4.4	31
3	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 200-207.	1.9	4
4	Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 81-88.	2.8	6
5	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology</i> , 2022, 162, 482-494.	1.3	46
6	A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 746-756.	1.3	18
7	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	2.9	10
8	Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. <i>Digestion</i> , 2022, 103, 169-173.	2.3	4
9	Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1320-1329.	3.7	8
10	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	1.3	28
11	AJM300 (carotegrast methyl), an oral antagonist of $\alpha 4$ -integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 648-657.	8.1	38
12	Lower effectiveness of intravenous steroid treatment for moderate to severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1569-1580.	3.7	8
13	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. <i>Crohn's & Colitis</i> 360, 2022, 4, .	1.1	8
14	Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1884-1892.	2.8	5
15	Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. <i>Digestive Diseases and Sciences</i> , 2021, 66, 577-586.	2.3	21
16	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 908-921.e6.	4.4	38
17	Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. <i>Journal of Gastroenterology</i> , 2021, 56, 147-157.	5.1	13
18	Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 943-950.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. <i>Intestinal Research</i> , 2021, 19, 53-61.	2.6	17
20	Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2116-2124.	2.8	4
21	Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF- α Agents in Patients with Ulcerative Colitis. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 117-122.	1.9	8
22	Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2091-2100.	2.8	11
23	Phase 1 study on the safety and efficacy of E6011, anti fractalkine antibody, in patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2180-2186.	2.8	11
24	A Case of Crohn's Disease with Cardiac Tamponade Caused by Tuberculous Pericarditis: Assessment of a Rare Phenomenon. <i>Healthcare (Switzerland)</i> , 2021, 9, 695.	2.0	2
25	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 2372-2384.	13.7	194
26	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 429-437.	8.1	34
27	Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study. <i>Intestinal Research</i> , 2021, 19, 301-312.	2.6	23
28	Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. <i>Journal of Gastroenterology</i> , 2021, 56, 843-855.	5.1	6
29	Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. <i>Journal of Gastroenterology</i> , 2021, 56, 999-1007.	5.1	3
30	Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNF- α -Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. <i>Digestion</i> , 2021, 102, 742-752.	2.3	8
31	Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. <i>Intestinal Research</i> , 2021, 19, 95-105.	2.6	14
32	Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. <i>Intestinal Research</i> , 2021, 19, 408-418.	2.6	13
33	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. <i>Intestinal Research</i> , 2021, 19, 448-460.	2.6	11
34	Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. <i>Intestinal Research</i> , 2021, 19, 419-429.	2.6	13
35	Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database. <i>PLoS ONE</i> , 2021, 16, e0258537.	2.5	5
36	PMO-31...Rapidly of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	OMO-2â€¦Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results. , 2021, , .		0
38	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology, 2020, 158, 537-549.e10.	1.3	130
39	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1102-1111.e5.	4.4	29
40	Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 225-232.	2.8	14
41	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. Journal of Crohn's and Colitis, 2020, 14, 617-623.	1.3	26
42	Effects of vedolizumab in Japanese patients with Crohnâ€™s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. Journal of Gastroenterology, 2020, 55, 291-306.	5.1	34
43	Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. Journal of Gastroenterology, 2020, 55, 390-400.	5.1	14
44	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitisâ€”one more arrow in the quiver of nonâ€”invasive diagnostics. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 403-403.	3.7	2
45	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-Î± Inhibitor Induction Therapy among Patients with Crohnâ€™s Disease. Inflammatory Intestinal Diseases, 2020, 5, 78-83.	1.9	6
46	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. Journal of Clinical Medicine, 2020, 9, 2286.	2.4	7
47	Ulcerative colitis. Nature Reviews Disease Primers, 2020, 6, 74.	30.5	678
48	Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1373-1383.	3.7	50
49	Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-. Journal of the Anus, Rectum and Colon, 2020, 4, 1-13.	1.1	21
50	A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohnâ€™s disease. Journal of Gastroenterology, 2020, 55, 615-626.	5.1	12
51	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Inflammatory Intestinal Diseases, 2020, 5, 27-35.	1.9	29
52	Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohnâ€™s disease in Japanese and Korean patients: the OPERA study. Intestinal Research, 2020, 18, 45-55.	2.6	7
53	Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intestinal Research, 2020, 18, 56-68.	2.6	6
54	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases, 2019, 4, 79-96.	1.9	53

#	ARTICLE	IF	CITATIONS
55	Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. <i>BMC Pediatrics</i> , 2019, 19, 351.	1.7	2
56	Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 131-143.	1.9	6
57	Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. <i>Journal of Gastroenterology</i> , 2019, 54, 891-896.	5.1	31
58	Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). <i>Journal of Gastroenterology</i> , 2019, 54, 860-870.	5.1	21
59	Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1097-1104.	1.3	15
60	Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. <i>PLoS ONE</i> , 2019, 14, e0212989.	2.5	59
61	Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. <i>PLoS ONE</i> , 2019, 14, e0212404.	2.5	9
62	Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOU and Ulcerative colitis: Registry and Social network). <i>BMJ Open</i> , 2019, 9, e030134.	1.9	4
63	Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. <i>Intestinal Research</i> , 2019, 17, 87-93.	2.6	8
64	Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. <i>Intestinal Research</i> , 2019, 17, 218-226.	2.6	2
65	Efficacy and safety of abrilumab, an $\alpha 4\beta 7$ integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. <i>Intestinal Research</i> , 2019, 17, 375-386.	2.6	17
66	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. <i>Intestinal Research</i> , 2019, 17, 504-515.	2.6	14
67	Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1485-1491.	2.8	16
68	Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 305-353.	5.1	427
69	Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 542-549.e1.	4.4	40
70	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 154, 935-947.	1.3	139
71	Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn's disease. <i>Journal of Gastroenterology</i> , 2018, 53, 907-915.	5.1	42
72	Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 394-401.	1.3	56

#	ARTICLE	IF	CITATIONS
73	A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2404-2412.	1.9	16
74	Efficacy of <i>Bifidobacterium breve</i> Fermented Milk in Maintaining Remission of Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1910-1919.	2.3	78
75	A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. <i>Journal of Gastroenterology</i> , 2018, 53, 387-396.	5.1	13
76	Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1031-1038.	2.8	24
77	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. <i>Journal of Gastroenterology</i> , 2018, 53, 494-506.	5.1	20
78	The Burden of Diverticular Disease and Its Complications: West versus East. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 61-68.	1.9	60
79	Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 1-10.	1.9	4
80	Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 25-31.	1.9	8
81	Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2018, 16, 255.	2.6	8
82	Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. <i>PLoS ONE</i> , 2018, 13, e0201956.	2.5	5
83	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. <i>Intestinal Research</i> , 2018, 16, 4.	2.6	32
84	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis: Capsule Scoring of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2641-2647.	1.9	19
85	Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1288-1294.	1.3	58
86	Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. <i>Intestinal Research</i> , 2018, 16, 233.	2.6	21
87	Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. <i>Intestinal Research</i> , 2018, 16, 494.	2.6	20
88	Seven days triple therapy for eradication of <i>Helicobacter pylori</i> does not alter the disease activity of patients with inflammatory bowel disease. <i>Intestinal Research</i> , 2018, 16, 609-618.	2.6	12
89	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. <i>Intestinal Research</i> , 2018, 16, 168.	2.6	8
90	5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. <i>Intestinal Research</i> , 2018, 16, 635-640.	2.6	5

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). <i>Journal of Gastroenterology</i> , 2017, 52, 1101-1111.	5.1	60
92	Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. <i>BMC Gastroenterology</i> , 2017, 17, 47.	2.0	18
93	2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 822-832.	1.9	20
94	Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. <i>Journal of Gastroenterology</i> , 2017, 52, 1031-1040.	5.1	10
95	The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1302-1308.	1.3	12
96	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 84-91.	1.3	100
97	Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey. <i>Journal of Gastroenterology</i> , 2017, 52, 555-567.	5.1	42
98	Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey. <i>Journal of Gastroenterology</i> , 2017, 52, 308-314.	5.1	35
99	Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. <i>Intestinal Research</i> , 2017, 15, 475.	2.6	21
100	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 228-235.	1.9	12
101	Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial. <i>Intestinal Research</i> , 2017, 15, 395.	2.6	33
102	Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2017, 15, 368.	2.6	9
103	Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 154-162.	1.9	13
104	Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. <i>PLoS ONE</i> , 2017, 12, e0185131.	2.5	16
105	Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study. <i>Intestinal Research</i> , 2017, 15, 358.	2.6	4
106	Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab. <i>Intestinal Research</i> , 2017, 15, 535.	2.6	1
107	A case of gastric mucosal prolapse polyp that was difficult to differentiate from duodenal submucosal tumor. <i>Progress of Digestive Endoscopy</i> , 2016, 88, 106-107.	0.0	0
108	Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. <i>Intestinal Research</i> , 2016, 14, 50.	2.6	7

#	ARTICLE	IF	CITATIONS
109	Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages. <i>Scientific Reports</i> , 2016, 6, 35014.	3.3	49
110	Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capsule endoscopy: SCHEMA study. <i>Endoscopy International Open</i> , 2016, 04, E589-E596.	1.8	9
111	Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. <i>Gastroenterology</i> , 2016, 151, 1122-1130.	1.3	171
112	Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 197-204.	0.9	16
113	Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1259-1266.	1.3	182
114	Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease. <i>Medicine (United States)</i> , 2016, 95, e3863.	1.0	77
115	Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 828-836.	1.3	42
116	Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1033-1041.	1.3	20
117	Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. <i>Drugs in R and D</i> , 2016, 16, 35-43.	2.2	2
118	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis: results from a multicenter prospective randomized controlled trial and its post hoc analysis. <i>Journal of Gastroenterology</i> , 2016, 51, 241-251.	5.1	93
119	A new start for 'Intestinal Research' as an official journal of AOCC. <i>Intestinal Research</i> , 2016, 14, 1.	2.6	0
120	An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. <i>BMC Gastroenterology</i> , 2015, 15, 163.	2.0	26
121	Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0125664.	2.5	2
122	A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter. <i>PLoS Genetics</i> , 2015, 11, e1005581.	3.5	94
123	Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. <i>PLoS ONE</i> , 2015, 10, e0131197.	2.5	14
124	Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. <i>Clinical Nutrition</i> , 2015, 34, 1202-1209.	5.0	31
125	Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 940-948.e3.	4.4	86
126	Safety and Efficacy of AJM300, an Oral Antagonist of α_4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 149, 1775-1783.e2.	1.3	120

#	ARTICLE	IF	CITATIONS
127	Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission. PLoS ONE, 2015, 10, e0140716.	2.5	40
128	Prominent Steatosis with Hypermetabolism of the Cell Line Permissive for Years of Infection with Hepatitis C Virus. PLoS ONE, 2014, 9, e94460.	2.5	32
129	Gastric emptying rate in subjects with malocclusion examined by [¹³ C] breath test. Orthodontic Waves, 2014, 73, 1-1.	0.2	0
130	Continuous low-dose irradiation by I-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin. Cancer Biology and Therapy, 2014, 15, 81-88.	3.4	6
131	The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNF± monoclonal antibodies. Journal of Gastroenterology, 2014, 49, 156-162.	5.1	105
132	Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology, 2014, 49, 283-294.	5.1	130
133	Which makes patients happier, surgery or anti-TNF therapy?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 272-273.	17.8	1
134	A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. Journal of Crohn's and Colitis, 2014, 8, 981-991.	1.3	49
135	Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 1407-1416.	1.3	28
136	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2014, 146, 85-95.	1.3	753
137	Obesity, type 2 diabetes, age, and female gender: significant risk factors in the development of alcoholic liver cirrhosis. Hepatology International, 2013, 7, 280-285.	4.2	14
138	Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. Journal of Gastroenterology, 2013, 48, 1006-1015.	5.1	32
139	Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. Journal of Gastroenterology, 2013, 48, 31-72.	5.1	109
140	Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. Journal of Crohn's and Colitis, 2013, 7, e49-e54.	1.3	16
141	Treatment Guidelines in Inflammatory Bowel Disease: The Japanese Perspectives. Digestive Diseases, 2013, 31, 363-367.	1.9	15
142	A case of single balloon endoscopy useful for diagnosis of pediatric jejunum ectopic pancreas. Progress of Digestive Endoscopy, 2013, 82, 164-165.	0.0	0
143	A case of idiopathic rectal perforation in a young patient. Progress of Digestive Endoscopy, 2013, 82, 178-179.	0.0	0
144	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut, 2012, 61, 241-247.	12.1	291

#	ARTICLE	IF	CITATIONS
145	Effects of family history on inflammatory bowel disease characteristics in Japanese patients. <i>Journal of Gastroenterology</i> , 2012, 47, 961-968.	5.1	38
146	Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 160-173.	1.3	106
147	Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. <i>Hepatology International</i> , 2012, 6, 744-752.	4.2	8
148	Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 803-808.	1.9	180
149	Hemobilia due to biliary intraepithelial neoplasia associated with Zollinger-Ellison syndrome. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 189-194.	0.8	3
150	Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. <i>Journal of Gastroenterology</i> , 2010, 45, 1129-1137.	5.1	38
151	Bouveret's syndrome with a concomitant incidental T1 gallbladder cancer. <i>Clinical Journal of Gastroenterology</i> , 2010, 3, 248-253.	0.8	6
152	Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 15-22.	1.9	88
153	Intestinal macrophage, "a double-edged sword" for homeostasis and inflammation in the gut. <i>Inflammation and Regeneration</i> , 2010, 30, 412-418.	3.7	0
154	An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment. <i>American Journal of Gastroenterology</i> , 2009, 104, 2990-2995.	0.4	117
155	Prevalence of ulcerative colitis and Crohn's disease in Japan. <i>Journal of Gastroenterology</i> , 2009, 44, 659-665.	5.1	227
156	A case of severe cholestatic jaundice with hyperthyroidism successfully treated with methimazole. <i>Clinical Journal of Gastroenterology</i> , 2009, 2, 315-319.	0.8	5
157	Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1259-1264.	1.9	82
158	A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis. <i>Gastroenterology</i> , 2008, 135, 400-409.	1.3	197
159	Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine. <i>Annals of Cancer Research and Therapy</i> , 2008, 16, 21-22.	0.3	0
160	A strategy aimed at low risk ESD and Four days clinical pathway for superficial gastric neoplasias. <i>Progress of Digestive Endoscopy</i> , 2008, 73, 58-61.	0.0	0
161	Novel pathophysiological concepts of inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2006, 41, 10-16.	5.1	147
162	A case of esophageal intramural pseudodiverticulosis on the whole esophagus. <i>Progress of Digestive Endoscopy</i> , 2006, 69, 50-51.	0.0	0

#	ARTICLE	IF	CITATIONS
163	A case report of cap polyposis with spontaneous remission. <i>Progress of Digestive Endoscopy</i> , 2006, 68, 140-141.	0.0	0
164	Is there a role for apheresis in gastrointestinal disorders?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 200-201.	1.7	24
165	Leukocytapheresis in Ulcerative Colitis: Results of a Multicenter Double-Blind Prospective Case-Control Study with Sham Apheresis as Placebo Treatment. <i>American Journal of Gastroenterology</i> , 2005, 100, 1362-1369.	0.4	127
166	Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. <i>Journal of Gastroenterology</i> , 2004, 39, 1158-1164.	5.1	98
167	A case of O-IIa esophageal carcinoma in situ developing along the long axis of the esophagus, which was resected endoscopically. <i>Progress of Digestive Endoscopy</i> , 2004, 64, 52-53.	0.0	0
168	A case of early stage gastric cancer spreading to the pyloric ring resected endoscopically. <i>Progress of Digestive Endoscopy</i> , 2004, 64, 70-71.	0.0	0
169	Usefulness of argon plasma coagulation using a double channel endoscope. <i>Progress of Digestive Endoscopy</i> , 2004, 64, 46-47.	0.0	0
170	Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. <i>Journal of Gastroenterology</i> , 2003, 38, 740-746.	5.1	116
171	Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column. <i>Current Pharmaceutical Design</i> , 2003, 9, 307-321.	1.9	176
172	Procedure of endoscopic hemostasis using a distal attachment and short clips against upper gastrointestinal bleeding. <i>Progress of Digestive Endoscopy</i> , 2003, 63, 26-28.	0.0	1
173	A case of recurrent simple ulcer after ileocecal resection for which endoscopic treatment with spraying of absolute ethanol was effective. <i>Progress of Digestive Endoscopy</i> , 2003, 62, 126-127.	0.0	1
174	Lack of common NOD2 variants in Japanese patients with Crohn's disease. <i>Gastroenterology</i> , 2002, 123, 86-91.	1.3	449
175	Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 160-168.	2.8	58
176	Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 763-769.	2.8	22
177	HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis. <i>Journal of Clinical Immunology</i> , 2001, 21, 381-389.	3.8	7
178	Measurement of Colonic Mucosal Concentrations of 5-Aminosalicylic Acid Is Useful for Estimating Its Therapeutic Efficacy in Distal Ulcerative Colitis: Comparison of Orally Administered Mesalamine and Sulfasalazine. <i>Inflammatory Bowel Diseases</i> , 2001, 7, 221-225.	1.9	82
179	A case of giant colonic lipoma for which endoscopic therapy was successful. <i>Progress of Digestive Endoscopy</i> , 2001, 58, 116-117.	0.0	0
180	Circulating autoantibodies against purified colonic mucin in ulcerative colitis. <i>Journal of Gastroenterology</i> , 2000, 35, 20-27.	5.1	64

#	ARTICLE	IF	CITATIONS
181	Effect of germinated barley foodstuff administration on mineral utilization in rodents. <i>Journal of Gastroenterology</i> , 2000, 35, 188-194.	5.1	8
182	Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis. <i>Journal of Gastroenterology</i> , 2000, 35, 214-220.	5.1	40
183	The role of IL-18 on the pathogenesis of Crohn's disease. <i>Japanese Journal of Clinical Immunology</i> , 2000, 23, 607-610.	0.0	0
184	Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis. <i>Journal of Clinical Immunology</i> , 1999, 19, 77-85.	3.8	8
185	Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model. <i>Immunologic Research</i> , 1999, 20, 251-259.	2.9	16
186	A case of asymptomatic amoebic colitis localized only in the cecum. <i>Progress of Digestive Endoscopy(1972)</i> , 1999, 54, 126-127.	0.0	0
187	Augmented levels of gastric mucosal leucocyte activation by infection with cagA gene-positive <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 294-300.	2.8	31
188	Predictive Factors of Response to Leukocytapheresis Therapy for Ulcerative Colitis. <i>Therapeutic Apheresis and Dialysis</i> , 1998, 2, 115-119.	0.6	24
189	A Case of Multiple Hepatoid Adenocarcinoma in the Duodenum, Ascending, Transverse Colon and Mediastinum. <i>Progress of Digestive Endoscopy(1972)</i> , 1998, 52, 74-77.	0.0	2
190	Two cases of ulcerative colitis which needed emergency surgery for massive hemorrhage and shock.. <i>Nihon Kyokyu Igakukai Zasshi</i> , 1998, 9, 60-65.	0.0	0
191	A Case of Cytomegalovirus Colitis. <i>Progress of Digestive Endoscopy(1972)</i> , 1998, 51, 108-111.	0.0	0
192	A Novel Therapy for Corticosteroid-Dependent or Corticosteroid-Resistant Patients with Ulcerative Colitis. <i>Internal Medicine</i> , 1997, 36, 317-318.	0.7	6
193	Preventive Medical Examinations for Colorectal Cancer in Japan to Reduce Mortality from Colorectal Cancer. <i>Digestive Endoscopy</i> , 1997, 9, 3-10.	2.3	1
194	Microvascular disturbances in the colonic mucosa in antibiotic-associated haemorrhagic colitis: Involvement of platelet aggregation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 681-685.	2.8	13
195	A Case of Left Ovarian Mature Teratoma Penetrating into the Rectum. <i>Progress of Digestive Endoscopy(1972)</i> , 1996, 49, 220-221.	0.0	1
196	Magnifying Endoscopic Observation of the Colonic Minute Lesions in Inflammatory Bowel Disease. <i>Progress of Digestive Endoscopy(1972)</i> , 1996, 49, 164-165.	0.0	0
197	Sulfhydryl blocker-induced colitis in the rat: Immunological changes in thymus gland and colonic mucosa. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 544-550.	2.8	2
198	Changes of Proliferative Activity and Phenotypes in Spontaneous Differentiation of a Colon Cancer Cell Line. <i>Japanese Journal of Cancer Research</i> , 1993, 84, 625-632.	1.7	26

#	ARTICLE	IF	CITATIONS
199	Significant changes in intestinal lymphatic system and immune response elicited by Peyer's patch excision in adult rats. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 63-69.	2.8	4
200	A Case of Crohn's Disease which Initially Presented with Diffuse Inflammation in the Rectum and Sigmoid Colon. <i>Digestive Endoscopy</i> , 1993, 5, 169-174.	2.3	1
201	Tissue-type plasminogen activator of colonic mucosa in ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1992, 37, 307-311.	2.3	8
202	Possible Involvement of Tissue-type Plasminogen Activator in Gastric Ulcer Formation – Biochemical Evaluation Using Biopsy Specimens From Gastric Mucosa –. <i>Digestive Endoscopy</i> , 1990, 2, 49-53.	2.3	2
203	Comparative, immunological studies on Lymphangiectasia of the small intestine revealed in protein losing gastroenteropathy and Behçet's disease. <i>Gastroenterologia Japonica</i> , 1976, 11, 88-99.	0.3	6
204	Usefulness of colestimide for diarrhea in postoperative Crohn's disease. <i>JGH Open</i> , 0, , .	1.6	0